'Obesity plus': What’s next for GLP-1s?
Novo Nordisk and Eli Lilly are set to make billions of dollars each year off their GLP-1s, but patients and prescribers are still eager for improved drugs, citing GI side effects, muscle loss and weight gain after stopping treatment.
Add in the potential for drugs like Novo’s semaglutide (marketed as Wegovy for weight loss and Ozempic for type 2 diabetes) and Lilly’s tirzepatide (approved as Zepbound for weight loss and Mounjaro for diabetes) to improve cardiometabolic function, and these drugs may tap into what industry insiders are now calling the “obesity plus” or “GLP-1 plus” opportunity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
